Company / Working Capital
Edgewise Therapeutics, Inc. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$516.0M
FY2025
5-year range
$273.3M / $516.0M
FY2021-FY2025
Trend
+14.3%
vs FY2024
Sector context
#90 of 213
Health Care
What the data says
At $516M, Edgewise Therapeutics, Inc.'s working capital ranks #90 of 213 in the Health Care sector. Improved from $310M to $516M over the past 2 years.
Based on SEC 10-K filings.
$516M in FY2025 with a 5-year CAGR of +32.7%.
Improved from $310M to $516M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +14.9%
- 5-Year CAGR
- +32.7%
- 10-Year CAGR
- -
Sector benchmark
#90 of 213 in Health CareTop 42% of 213This company $516.0M Sector average $934.6M
▼
-44.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +32.7%, indicating consistent growth.
- In FY2025, working capital increased 14.3% year-over-year.
- Ranks #90 out of 213 companies in the Health Care sector.
- Lowest working capital in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $516.0M | +14.3% |
| FY2024 | $451.6M | +45.6% |
| FY2023 | $310.2M | -8.9% |
| FY2022 | $340.4M | +24.6% |
| FY2021 | $273.3M | +118.1% |
| FY2020 | $125.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026